ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer

Lv,Xiaohong; Li,Yang; Qian,Ming; Ma,Chengyuan; Jing,Hongyu; Wen,Zhongmei; Qian,Donghua

doi:10.3892/mmr.2014.2029

ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer

Authors:
- Xiaohong Lv
- Yang Li
- Ming Qian
- Chengyuan Ma
- Hongyu Jing
- Zhongmei Wen
- Donghua Qian
View Affiliations

Affiliations: Department of Respiration, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Prosthodontics, Stomatological Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Neurosurgery, The First Hospital o f Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: March 7, 2014 https://doi.org/10.3892/mmr.2014.2029
Pages: 1935-1940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A disintegrin and metalloprotease (ADAM) 17 has been implicated in the tumor progression of various types of solid tumor; however, little is known about its role in non-small cell lung carcinoma (NSCLC). The present study evaluated whether the downregulation of ADAM17 affects cell proliferation, the cell cycle, cell migration and cell invasion in NSCLC. A recombinant lentiviral small hairpin RNA (shRNA) expression vector carrying ADAM17 was constructed and then infected into A549 cells, a human NSCLC cell line. Cell proliferation, cell cycle progression, cell migration and cell invasion were determined following the downregulation of ADAM17 by siRNA. It was revealed that downregulation of ADAM17 expression using an RNA silencing approach in A549 tumor cells significantly suppressed cell proliferation and invasion in vitro, and tumor growth in vivo. These data suggested that ADAM17 is an important regulator of the tumorigenic properties of human NSCLC and may be used as a potential anticancer therapeutic target in NSCLC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J and Bischof M: Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 10:1052010. View Article : Google Scholar : PubMed/NCBI
3	Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren H and Klomp HM: Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 30:2731–2738. 2012. View Article : Google Scholar : PubMed/NCBI
4	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fischer OM, Hart S, Gschwind A, Prenzel N and Ullrich A: Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol. 24:5172–5183. 2004. View Article : Google Scholar : PubMed/NCBI
6	Mahimkar RM, Visaya O, Pollock AS and Lovett DH: The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J. 385:461–468. 2005. View Article : Google Scholar : PubMed/NCBI
7	Singh B, Schneider M, Knyazev P and Ullrich A: UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int J Cancer. 124:531–539. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kenny PA and Bissell MJ: Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 117:337–345. 2007. View Article : Google Scholar : PubMed/NCBI
9	McGowan PM, Ryan BM, Hill AD, McDermott E, O’Higgins N and Duffy MJ: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ni SS, Zhang J, Zhao WL, Dong XC and Wang JL: ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival. Tumour Biol. 34:1813–1818. 2013. View Article : Google Scholar : PubMed/NCBI
11	Huang WY, Chen DH, Ning L and Wang LW: siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells. Asian Pac J Cancer Prev. 13:1823–1827. 2012. View Article : Google Scholar : PubMed/NCBI
12	Black RA: Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol. 34:1–5. 2002. View Article : Google Scholar : PubMed/NCBI
13	Primakoff P and Myles DG: The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 16:83–87. 2000. View Article : Google Scholar : PubMed/NCBI
14	Duffy MJ, McKiernan E, O’Donovan N and McGowan P: Role of ADAMs in cancer formation and progression. Clin Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
15	Duffy MJ, McKiernan E, O’Donovan N and McGowan P: The role of ADAMs in disease pathophysiology. Clin Chim Acta. 403:31–36. 2009. View Article : Google Scholar : PubMed/NCBI
16	Takamune Y, Ikebe T, Nagano O and Shinohara M: Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem Biophys Res Commun. 365:393–398. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther. 8:1045–1105. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ding X, Yang LY, Huang GW, Wang W and Lu WQ: ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol. 10:2735–2739. 2004.PubMed/NCBI
19	Gschwind A, Hart S, Fischer OM and Ullrich A: TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 22:2411–2421. 2003. View Article : Google Scholar : PubMed/NCBI
20	Hart S, Fischer OM and Ullrich A: Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64:1943–1950. 2004.PubMed/NCBI
21	Niculescu AB III, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 18:629–643. 1998.PubMed/NCBI
22	Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY and Chiou SH: miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 73:3425–3440. 2013. View Article : Google Scholar : PubMed/NCBI
23	Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci. 98:621–628. 2007. View Article : Google Scholar : PubMed/NCBI
24	Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A and Cataldo D: Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 90:369–379. 2008. View Article : Google Scholar : PubMed/NCBI